Introduction {#s1}
============

A higher body mass index (BMI) is a strong predictor of type 2 diabetes (T2D), with a linear increase in diabetes risk across the whole spectrum of BMI [@pmed.1001230-BarrettConnor1]. Although diabetes risk is highest in obese people with BMI≥30 kg/m^2^, a great proportion of future cases comes from the large population of overweight individuals with a BMI between 25 and 30 kg/m^2^ [@pmed.1001230-Wang1]. Recent national figures from the US and UK suggest that at least a third of the population is now overweight and another third (24% UK) is obese [@pmed.1001230-Flegal1],[@pmed.1001230-Zaninotto1], with severe implications for the future burden of diabetes.

The Diabetes Prevention Program has shown that individual-level lifestyle intervention can reduce the incidence of diabetes by over 50% in high-risk individuals [@pmed.1001230-Knowler1], an effect that persists for at least 10 y [@pmed.1001230-Knowler2]. Current clinical practice generally relies on measurement of BMI to identify individuals at increased risk of diabetes and other adiposity-related morbidity and mortality. However, due to their high prevalence, it is financially and logistically difficult to test and intervene on all overweight and obese individuals.

BMI provides no information about body fat distribution, which distinguishes the large amount of adipose tissue located subcutaneously from the smaller amount of intra-abdominal visceral fat, known to predict the development of diabetes over and above BMI [@pmed.1001230-Wang1],[@pmed.1001230-Vazquez1],[@pmed.1001230-Freemantle1]. Waist circumference (WC) is a simple measure that can be used to diagnose abdominal obesity and identify individuals at increased risk of T2D [@pmed.1001230-Klein1]. Information about WC is therefore likely to be useful in distinguishing high- and low-risk individuals at different levels of BMI, which is important for targeting those at highest absolute risk for individually focused lifestyle intervention to prevent T2D.

However, WC is not routinely assessed in clinical practice for a range of reasons [@pmed.1001230-Dunkley1]. Although measurement is relatively simple and cheap, it does require some training and standardisation, and this has been cited as one reason for its limited use. Another explanation is that practitioners do not appreciate the relevance of the additional information that is derived from measuring WC over and above BMI [@pmed.1001230-Dunkley1]. This may be because earlier studies were generally too small to estimate T2D incidence rates at different levels of BMI and WC with the precision required to guide clinical decision making or inform policy recommendations. In addition, men and women differ in the distribution of their overall and abdominal body fat, but only large-scale studies including men and women are adequately powered to investigate sex differences in associations of BMI and WC with T2D with confidence.

We use data from the European InterAct study, a case-cohort study of 12,403 cases of incident T2D and a subcohort of 16,154 participants, conducted in 26 centres in eight European countries to estimate the relative and cumulative risk of diabetes at different levels of BMI and WC, separately in men and women.

Methods {#s2}
=======

Population {#s2a}
----------

The design and methods of the InterAct case-cohort study have previously been described in detail [@pmed.1001230-Langenberg1]. InterAct Consortium partners identified individuals with T2D in European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts between 1991 and 2007 from eight of the ten countries participating in EPIC (26 centres). Prevalent diabetes was identified on the basis of baseline self-report of a history of diabetes, doctor-diagnosed diabetes, diabetes drug use, or evidence of diabetes after baseline with a date of diagnosis earlier than the baseline recruitment date. All ascertained cases with any evidence of diabetes at baseline were excluded. Ascertainment of incident T2D involved a review of the existing EPIC datasets at each centre using multiple sources of evidence including self-report, linkage to primary-care registers, secondary-care registers, medication use (drug registers), hospital admissions and mortality data. Information from any follow-up visit or external evidence with a date later than the baseline visit was used. To increase the specificity of the case definition, we sought further evidence for all cases with information on incident T2D from fewer than two independent sources at a minimum, which included individual medical records review in some centres. Cases in Denmark and Sweden were not ascertained by self-report, but identified via local and national diabetes and pharmaceutical registers, and hence all ascertained cases were considered to be verified. Follow-up was censored at the date of diagnosis, 31 December 2007, or the date of death, whichever occurred first. A total of 340,234 participants of European descent were followed up for 3.99 million person-years (mean \[range\] of follow-up 11.7 \[0--17.5\] y), during which 12,403 verified incident cases of T2D were identified [@pmed.1001230-Langenberg1]. Individuals without stored blood (*n* = 109,625) or without reported diabetes status (*n* = 5,821) were excluded. A centre-stratified, random subcohort of 16,835 individuals was selected; after exclusion of 548 individuals with prevalent diabetes and 133 with unknown diabetes status, the subcohort included 16,154 individuals for analysis. Due to the random selection, this subcohort also included a random set of 778 individuals who had developed incident T2D during follow-up. Participants in the random subcohort were similar to all EPIC participants eligible for inclusion in InterAct [@pmed.1001230-Langenberg1]. InterAct cases were followed-up for a mean (standard deviation \[SD\]) of 6.9 (3.3) y; 49.8% were men. The overall incidence in InterAct was 3.8 per 1,000 person-years of follow-up; country-specific rates are included in the InterAct cohort description [@pmed.1001230-Langenberg1].

Measurements {#s2b}
------------

Weight and height were measured with participants not wearing shoes and in light clothing or underwear in the majority of centres, as described previously [@pmed.1001230-Haftenberger1]. WC was measured either at the narrowest circumference of the torso or at the midpoint between the lower ribs and the iliac crest. Hip circumference was measured horizontally at the level of the largest lateral extension of the hips or over the buttocks. For a subset of the Oxford (UK) participants (*n* = 363), only self-reported waist and hip circumferences were available. Each participant\'s body weight and waist and hip circumferences were corrected for the clothing worn during measurement in order to reduce heterogeneity due to protocol differences among centres [@pmed.1001230-Pischon1]. Correction included adjustment for self-reporting in Oxford participants using a prediction equation based on a comparison of self-reported and measured data in a sample of 5,000 of the Oxford general population [@pmed.1001230-Haftenberger1],[@pmed.1001230-Spencer1]. BMI was calculated as weight (in kilograms)/height (in metres) squared. Waist-hip ratio was calculated and expressed as a percentage. Measures of waist or hip circumference were not performed at the centre in Umea, Sweden (*n* = 1,845), and were missing in an additional 173 and 193 InterAct participants for waist and hip, respectively.

As part of EPIC, standardised information on education and smoking status was collected by questionnaire at baseline [@pmed.1001230-Riboli1]. Physical activity was assessed using a brief questionnaire covering occupation and recreational activity [@pmed.1001230-Day1],[@pmed.1001230-Wareham1].

Statistical Analysis {#s2c}
--------------------

Characteristics of the subcohort are described using summary statistics (means, SDs, frequencies, and percentages) separately for men and women. Associations between anthropometric variables and the hazard of diabetes were estimated using Prentice-weighted Cox regression models with age as the underlying time scale, separately within each centre and then combined across centres using random effects meta-analysis [@pmed.1001230-Langenberg1]. We calculated internally derived sex-specific standardised scores based on means and SDs within the subcohort for each anthropometric measure. We divided study participants into normal weight (BMI 18.5--24.9 kg/m^2^), overweight (25.0--29.9 kg/m^2^), or obese (≥30 kg/m^2^) based on current World Health Organization criteria [@pmed.1001230-World1], and used sex-specific cut-offs to define WC as normal (\<94 cm \[\<34.6 inches\] in men and \<80 cm \[31.5 inches\] in women), moderately increased (94--102 cm \[34.6--40 inches\] in men and 80--88 cm \[31.5--35 inches\] in women), or large (≥102 cm \[≥40 inches\] in men and ≥88 cm \[≥35 inches\] in women) [@pmed.1001230-World1],[@pmed.1001230-National1]. We excluded 189 participants (172 subcohort members and 17 cases from outside the subcohort) who were underweight (BMI\<18.5 kg/m^2^) from all analyses. Using standardised, continuous measures and categorical BMI and WC variables, we compared the effect estimates for associations between each anthropometric measure and the risk of diabetes, separately for men and women, before and after adjustments. Adjustments included other anthropometric measures, smoking, education, and physical activity, as specified for all models in the corresponding tables.

Where heterogeneity was observed in the effect estimates between centres, meta-regression was used to explore the extent to which the average age, BMI, or WC in each centre explained the heterogeneity. To assess whether the effect estimate of WC differed between men and women, a sex by WC (continuous variable) interaction term was included in the centre-specific Prentice-weighted Cox regression models, and the estimated interaction coefficients were then combined across centres using random effects meta-analysis. A similar analysis was performed to assess the evidence for a BMI group by WC group interaction using standard, clinical cut-offs.

To investigate the hazard ratio (HR) of diabetes by BMI and WC levels in more detail, we further subdivided study participants who had measures of BMI and WC into six BMI groups (18.5--22.4, 22.5--24.9, 25--27.4, 27.5--29.9, 30.0--34.9, and ≥35 kg/m^2^). Analyses were performed using Stata version 12 (StataCorp) Within Stata, the --st- suite of commands for performing survival analysis was used.

To estimate the cumulative incidence of diabetes we performed bootstrap sampling using the Stata bsample command to recreate the full cohort by resampling with replacement from the subcohort, according to the BMI and WC distributions within the subcohort. This made it possible to estimate absolute cumulative incidences (one minus the Kaplan-Meier estimate of the survivor function) for normal, increased, and large WC groups separately within the groups of normal, overweight, and obese men and women.

Results {#s3}
=======

Characteristics of men and women who were part of the subcohort are shown in [Tables 1](#pmed-1001230-t001){ref-type="table"} and [2](#pmed-1001230-t002){ref-type="table"}. A total of 50.0% of men and 33.8% of women were overweight, and 16.4% of men and 15.8% of women were obese. Overweight or obese men and women were shorter and had larger WCs and waist-hip ratios than participants with normal baseline BMI (all *p*\<0.001). Overweight or obese men and women were more likely to be physically inactive and to be educated at primary school level or less (all *p*\<0.001). While obese men were less likely to be never smokers and more likely to be former smokers, the opposite was observed in obese women, who were more likely to be never smokers and less likely to be former or current smokers (all *p*\<0.001).

10.1371/journal.pmed.1001230.t001

###### Characteristics of the subcohort by BMI group in men of the InterAct study.

![](pmed.1001230.t001){#pmed-1001230-t001-1}

  Characteristic                                                     Missing (Percent)   Normal, 18.5--24.9 kg/m^2^ (*n* = 2,026)   Overweight, 25.0--29.9 kg/m^2^ (*n* = 3,028)   Obese, ≥30.0 kg/m^2^ (*n* = 996)   Total (*n* = 6,050)                         
  ----------------------------------------------------------------- ------------------- ------------------------------------------ ---------------------------------------------- ---------------------------------- --------------------- ------- ------ ------- -------
  **Age (years)**                                                            0                             52.0                                         9.9                                      53.2                         8.5           53.6    7.9    52.9     8.9
  **Weight (kilograms)**                                                    0.2                            71.3                                         7.2                                      82.0                         7.7           96.0    11.0   80.7    11.7
  **Height (centimetres)**                                                  0.2                           175.8                                         7.2                                     173.5                         7.1           171.9   7.7    174.0    7.4
  **WC (centimetres)** [a](#nt102){ref-type="table-fn"}                     3.4                            86.2                                         6.3                                      96.3                         6.3           108.5   7.6    95.1    10.1
  **Waist-hip ratio (percent)** [a](#nt102){ref-type="table-fn"}            3.4                            90.2                                         5.4                                      94.9                         5.5           99.0    5.8    94.1     6.4
  **Weight at age 20 y (kilograms)**                                       22.0                            67.3                                         7.6                                      70.4                         8.2           75.1    10.0   69.8     8.6
  **Change in weight (kilograms)**                                         22.0                            4.5                                          6.8                                      13.3                         7.8           24.2    10.5   11.4    10.2
  **Duration of follow-up (years)**                                         0.0                                                                                                                                                                                   
  Non-case                                                                                                 12.1                                         2.3                                      12.2                         2.2           12.1    2.5    12.2     2.3
  Incident diabetes case                                                                                   6.8                                          3.3                                      7.3                          3.1            6.8    3.3     7.1     3.2
  **WC groups** [a](#nt102){ref-type="table-fn"}                            3.4                                                                                                                                                                                   
  \<94 cm                                                                                                  77.7                                        1,574                                     30.6                         927            1.1     11    41.7    2,529
  ≥94--101.9 cm                                                                                            9.8                                          198                                      45.2                        1,369          15.0    149    28.3    1,716
  ≥102 cm                                                                                                  0.4                                           8                                       16.7                         507           79.5    792    21.5    1,307
  **Physical activity**                                                     0.6                                                                                                                                                                                   
  Inactive                                                                                                 16.1                                         327                                      18.3                         555           22.6    225    18.4    1,115
  Moderately inactive                                                                                      29.8                                         603                                      31.5                         954           28.7    286    30.4    1,845
  Moderately active                                                                                        26.1                                         529                                      24.6                         746           24.7    246    25.1    1,525
  Active                                                                                                   26.0                                         526                                      24.1                         731           22.9    228    24.5    1,490
  **Highest school level**                                                  0.7                                                                                                                                                                                   
  None                                                                                                     1.9                                           38                                      5.7                          174           11.8    118     5.4     330
  Primary                                                                                                  26.1                                         529                                      35.8                        1,083          42.2    420    33.6    2,037
  Technical                                                                                                24.2                                         490                                      22.7                         686           18.9    188    22.6    1,370
  Secondary                                                                                                15.4                                         312                                      12.2                         370            9.7     97    12.9     786
  Further education                                                                                        30.6                                         619                                      22.1                         670           15.6    155    23.8    1,445
  **Smoking status**                                                        0.5                                                                                                                                                                                   
  Never                                                                                                    34.3                                         694                                      31.0                         938           26.4    263    31.3    1,900
  Former                                                                                                   32.0                                         649                                      37.8                        1,146          40.0    398    36.2    2,197
  Current                                                                                                  32.3                                         655                                      30.1                         911           32.5    324    31.3    1,901
  **Family history of diabetes** [b](#nt103){ref-type="table-fn"}           8.9                                                                                                                                                                                   
  Yes                                                                                                      11.3                                         142                                      16.4                         260           17.3     69    14.5     471
  No                                                                                                       88.7                                        1,117                                     83.6                        1,327          82.7    329    85.5    2,773

Data are means and SDs for continuous and percentages and frequencies for categorical variables. Twenty men in the subcohort were underweight (BMI\<18.5 kg/m^2^) and were excluded from this table; 41 men in the subcohort had missing values for BMI and were excluded from this table.

Data on WC and waist-hip ratio were not collected at the centre in Umea, Sweden (excluded from these summaries).

Family history data were not collected at the centres in Italy, Spain, Oxford, or Heidelberg, so these countries have been excluded when calculating percentages of individuals with/without a family history of diabetes.

10.1371/journal.pmed.1001230.t002

###### Characteristics of the subcohort by BMI group in women of the InterAct study.

![](pmed.1001230.t002){#pmed-1001230-t002-2}

  Characteristic                                                     Missing (Percent)   Normal, 18.5--24.9 kg/m^2^ (*n* = 4,942)   Overweight, 25.0--29.9 kg/m^2^ (*n* = 3,322)   Obese, ≥30.0 kg/m^2^ (*n* = 1,558)   Total (*n* = 9,822)                          
  ----------------------------------------------------------------- ------------------- ------------------------------------------ ---------------------------------------------- ------------------------------------ --------------------- ------- ------- ------- -------
  **Age (years)**                                                           0.0                            51.1                                         9.6                                       53.3                          8.9           53.2     8.4    52.1     9.3
  **Weight (kilograms)**                                                    0.4                            59.6                                         6.1                                       70.0                          6.3           84.7    11.0    66.8    11.7
  **Height (centimetres)**                                                  0.2                           162.9                                         6.5                                      160.4                          6.4           158.8    6.8    161.4    6.7
  **WC (centimetres)** [a](#nt105){ref-type="table-fn"}                     3.4                            73.8                                         6.0                                       84.7                          6.5           98.1     9.2    81.2    11.2
  **Waist-hip ratio (percent)** [a](#nt105){ref-type="table-fn"}            3.5                            77.1                                         5.5                                       81.4                          5.9           85.0     6.4    79.8     6.5
  **Weight at age 20 y (kilograms)**                                       38.8                            55.0                                         6.7                                       57.1                          7.2           61.3    10.4    56.4     7.7
  **Change in weight (kilograms)**                                         38.8                            5.1                                          6.5                                       14.1                          7.0           26.1    11.5    10.6    10.4
  **Duration of follow-up (years)**                                         0.0                                                                                                                                                                                      
  Non-case                                                                                                 12.1                                         1.9                                       12.3                          1.9           12.3     2.0    12.2     1.9
  Incident diabetes case                                                                                   8.0                                          3.2                                       7.7                           3.1            7.0     3.1     7.4     3.1
  **WC groups** [a](#nt105){ref-type="table-fn"}                            3.4                                                                                                                                                                                      
  \<80 cm                                                                                                  78.2                                        3,863                                      20.7                          688            0.8     13     47.0    4,691
  ≥80--87.9 cm                                                                                             13.4                                         661                                       45.5                         1,513           9.1     141    23.2    2,315
  ≥88 cm                                                                                                   1.8                                           87                                       29.7                          988           86.6    1,350   24.3    2,425
  **Physical activity**                                                     0.7                                                                                                                                                                                      
  Inactive                                                                                                 20.1                                         992                                       29.1                          966           42.0     655    26.5    2,648
  Moderately inactive                                                                                      35.4                                        1,750                                      35.5                         1,179          31.1     485    34.7    3,462
  Moderately active                                                                                        23.7                                        1,171                                      18.8                          625           14.2     221    20.6    2,059
  Active                                                                                                   19.6                                         969                                       15.6                          518           11.4     177    16.9    1,690
  **Highest school level**                                                  1.2                                                                                                                                                                                      
  None                                                                                                     2.4                                          119                                       11.3                          374           23.5     366     8.6     860
  Primary                                                                                                  25.8                                        1,274                                      38.6                         1,281          39.8     620    32.1    3,204
  Technical                                                                                                24.9                                        1,231                                      22.8                          757           17.7     276    23.0    2,299
  Secondary                                                                                                20.3                                        1,003                                      13.5                          449            8.4     131    16.3    1,624
  Further education                                                                                        24.7                                        1,220                                      12.2                          405            8.3     130    18.0    1,796
  **Smoking status**                                                        0.7                                                                                                                                                                                      
  Never                                                                                                    50.0                                        2,471                                      58.6                         1,948          66.6    1,037   55.4    5,527
  Former                                                                                                   22.7                                        1,122                                      20.8                          690           17.5     272    21.1    2,104
  Current                                                                                                  26.2                                        1,294                                      19.7                          655           14.8     231    22.4    2,238
  **Family history of diabetes** [b](#nt106){ref-type="table-fn"}           7.2                                                                                                                                                                                      
  Yes                                                                                                      17.4                                         531                                       22.4                          357           27.3     158    20.1    1,046
  No                                                                                                       82.6                                        2,513                                      77.6                         1,237          72.7     420    80.0    4,170

Data are means and SDs for continuous and percentages and frequencies for categorical variables. 152 women in the subcohort were underweight (BMI\<18.5 kg/m^2^) and were excluded from this table; 69 women in the subcohort had missing values for BMI and were excluded from this table.

Data on WC and waist-hip ratio were not collected at the centre in Umea, Sweden (excluded from these summaries).

Family history data were not collected at the centres in Italy, Spain, Oxford, or Heidelberg, so these countries have been excluded when calculating percentages of individuals with/without a family history of diabetes.

Contributions of BMI and Waist Circumference to the Hazard of T2D {#s3a}
-----------------------------------------------------------------

Significant, positive associations between both BMI and WC and the hazard of T2D were observed across all countries and centres in men and women ([Figures 1](#pmed-1001230-g001){ref-type="fig"}--[4](#pmed-1001230-g004){ref-type="fig"}). The pooled effect estimate (HR) for a 1 SD increase in BMI (SD 3.6 kg/m^2^ in men, 4.4 kg/m^2^ in women) was 1.93 (95% confidence interval 1.81; 2.06) in men and 2.07 (1.94; 2.21) in women; corresponding estimates for WC (SD 10.0 cm in men, 11.2 cm in women) were 1.95 (1.83; 2.08) in men and 2.43 (2.23; 2.64) in women ([Figures 1](#pmed-1001230-g001){ref-type="fig"}--[4](#pmed-1001230-g004){ref-type="fig"}; [Table 3](#pmed-1001230-t003){ref-type="table"}). There was heterogeneity between centres in the HRs for both BMI and WC ([Figures 1](#pmed-1001230-g001){ref-type="fig"}--[4](#pmed-1001230-g004){ref-type="fig"}), which was not explained by differences in the average age of participants in the different centres. A higher average WC was associated with a lower HR per 1 SD increase in BMI; inclusion of average WC in a meta-regression model reduced the *I* ^2^ values from 48% to 0% in men and from 59% to 52% in women. However, average BMI did not explain the heterogeneity in the WC to T2D associations in either men or women. There was no significant interaction between BMI and WC in either men (interaction parameter estimate 0.97 \[0.85; 1.11\], *p* = 0.66) or women (interaction parameter estimate 1.10 \[0.99; 1.22\], *p* = 0.073).

![Hazard ratios for type 2 diabetes per 1 SD increase in BMI (SD = 3.6 kg/m^2^) in men.\
Heterogeneity between centres: *I* ^2^ = 48% (*p* = 0.012). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are combined using random effects meta-analysis.](pmed.1001230.g001){#pmed-1001230-g001}

![Hazard ratios for type 2 diabetes per 1 SD increase in BMI (SD = 4.4 kg/m^2^) in women.\
Heterogeneity between centres: *I* ^2^ = 59% (*p* = 0.012). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are combined using random effects meta-analysis.](pmed.1001230.g002){#pmed-1001230-g002}

![Hazard ratios for type 2 diabetes per 1 SD increase in WC (SD = 10.0 cm) in men.\
Heterogeneity between centres: *I* ^2^ = 31% (*p* = 0.11). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are combined using random effects meta-analysis.](pmed.1001230.g003){#pmed-1001230-g003}

![Hazard ratios for type 2 diabetes per 1 SD increase in WC (SD = 11.2 cm) in women.\
Heterogeneity between centres: *I* ^2^ = 69% (*p*\<0.001). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are combined using random effects meta-analysis.](pmed.1001230.g004){#pmed-1001230-g004}

10.1371/journal.pmed.1001230.t003

###### Anthropometric measures and incident type 2 diabetes.

![](pmed.1001230.t003){#pmed-1001230-t003-3}

  Measure                                                        Men          Women               
  ------------------------------------------------------------- ------ ------------------- ------ -------------------
  **BMI**                                                                                         
  18.5--24.9 kg/m^2^                                                            1                          1
  25.0--29.9 kg/m^2^                                                    2.84 (2.33, 3.45)          3.81 (3.18, 4.58)
  ≥30.0 kg/m^2^                                                         7.58 (6.00, 9.57)          11.6 (9.20, 14.5)
  **WC**                                                                                          
  \<94/80 cm                                                                    1                          1
  ≥94--101.9/80--87.9 cm                                                2.40 (2.01, 2.88)          3.02 (2.61, 3.48)
  ≥102/88 cm                                                            5.36 (4.38, 6.54)          11.3 (9.15, 13.9)
  **Per 1 SD increase in BMI**                                   3.6                        4.4   
  Unadjusted                                                            1.93 (1.81, 2.06)          2.07 (1.94, 2.21)
  Adjusted for WC                                                       1.49 (1.27, 1.73)          1.15 (1.02, 1.30)
  Adjusted for WC, physical activity, smoking, and education            1.58 (1.36, 1.83)          1.16 (1.01, 1.34)
  **Per 1 SD increase in WC**                                    10.0                       11.2  
  Unadjusted                                                            1.95 (1.83, 2.08)          2.43 (2.23, 2.64)
  Adjusted for height                                                   2.03 (1.88, 2.20)          2.46 (2.27, 2.68)
  Adjusted for BMI                                                      1.39 (1.19, 1.63)          2.14 (1.87, 2.45)
  Adjusted for BMI, physical activity, smoking, and education           1.37 (1.19, 1.58)          2.25 (1.90, 2.66)
  **Per 1 SD increase in waist-hip ratio**                       6.3                        6.5   
  Unadjusted                                                            1.81 (1.61, 2.03)          2.15 (1.93, 2.40)
  Adjusted for BMI                                                      1.38 (1.25, 1.52)          1.71 (1.57, 1.86)
  Adjusted for BMI, physical activity, smoking, and education           1.33 (1.21, 1.47)          1.75 (1.58, 1.93)

HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are combined using random effects meta-analysis.

Differences in Associations between Men and Women {#s3b}
-------------------------------------------------

The stronger association between WC and incident T2D in women, compared to men, became more apparent in models mutually adjusting for WC and BMI ([Table 3](#pmed-1001230-t003){ref-type="table"}). While the independent contributions of a sex-specific SD increase in WC and BMI to the hazard of diabetes were of similar magnitude in men (1.39 \[1.19; 1.63\] for WC and 1.49 \[1.27; 1.73\] for BMI), the increased hazard of diabetes conveyed by a larger WC as opposed to higher BMI was much larger in women (2.14 \[1.87; 2.45\] for WC and 1.15 \[1.02; 1.30\] for BMI). A disproportionately increased HR of diabetes in women (HR 11.3 \[9.15; 13.9\]) compared to men (HR 5.36 \[4.38; 6.54\]; [Table 3](#pmed-1001230-t003){ref-type="table"}) was also seen using sex-specific cut-offs clinically used to identify individuals with central adiposity and excess visceral fat (\>102 cm \[40 inches\] in men and \>88 cm \[35 inches\] in women). Consistently greater HRs were observed in women across all study centres ([Figure S1](#pmed.1001230.s001){ref-type="supplementary-material"}), with sex ratios (HR~women~/HR~men~) ranging from 1.03 to 3.31 and a pooled sex ratio of 1.69 (1.42; 2.02). The higher hazard associated with greater WC in women was not explained by confounding by BMI, since the BMI adjusted pooled sex ratio was 1.60 (1.34; 1.90).

Hazard Ratio of Diabetes at Different Levels of Waist Circumference and BMI {#s3c}
---------------------------------------------------------------------------

BMI and WC are highly positively correlated (*r* = 0.85 in men and 0.87 in women in the subcohort). Therefore, too few men and women with a BMI of 18.5--22.4 kg/m^2^ had a WC greater than or equal to 94/80 cm (*n* = 130) and too few men with a BMI of 22.5--24.9 kg/m^2^ had a WC greater than or equal to 102 cm (*n* = 13) to contribute to stratified analyses ([Tables 4](#pmed-1001230-t004){ref-type="table"} and [5](#pmed-1001230-t005){ref-type="table"}). The same was true for participants with a BMI of 30--34.9 kg/m^2^ and a WC lower than 94/80 cm (*n* = 49), or those with a BMI greater or equal to 35 kg/m^2^ and a WC lower than 102/88 cm (*n* = 14).

10.1371/journal.pmed.1001230.t004

###### Combinations of BMI and waist circumference groups and type 2 diabetes in men.

![](pmed.1001230.t004){#pmed-1001230-t004-4}

  Weight Category    BMI (kg/m^2^)      WC (centimetres)                              
  ----------------- --------------- ------------------------- ----------------------- -----------------------
  **Underweight**       \<18.5                                                        
                                              20/3                      0/0                     0/0
  **Normal**          18.5--22.4     **1 (Reference group)**                          
                                             625/109                    8/3                     0/0
                      22.5--24.9      **1.53 (1.20, 1.95)**    **3.00 (1.84, 4.89)**  
                                            1,412/375                 308/120                  13/5
  **Overweight**      25.0--27.4      **2.76 (1.74, 4.37)**    **4.49 (2.74, 7.36)**   **5.67 (2.84, 11.3)**
                                            1,203/439                1,328/634                248/137
                      27.5--29.9      **3.77 (2.53, 5.61)**    **6.05 (3.87, 9.45)**   **8.91 (5.69, 13.9)**
                                             233/97                  1,335/749               1,044/707
  **Obese**           30.0--34.9                               **7.48 (4.55, 12.3)**   **13.3 (8.32, 21.1)**
                                              27/16                   314/183               2,111/1,550
                         ≥35.0                                                         **22.0 (14.3, 33.8)**
                                               0/0                      5/4                   557/470

HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Country-specific estimates are combined using random effects meta-analysis. Sample size and case number stated per cell.

10.1371/journal.pmed.1001230.t005

###### Combinations of BMI and waist circumference groups and type 2 diabetes in women.

![](pmed.1001230.t005){#pmed-1001230-t005-5}

  Weight Category    BMI (kg/m^2^)      WC (centimetres)                              
  ----------------- --------------- ------------------------- ----------------------- -----------------------
  **Underweight**       \<18.5                                                        
                                             139/13                     0/0                     1/1
  **Normal**          18.5--22.4     **1 (Reference group)**                          
                                            2,325/257                 108/28                   14/4
                      22.5--24.9      **1.71 (1.39, 2.09)**    **3.47 (2.70, 4.45)**   **5.55 (3.44, 8.95)**
                                            2,100/344                 798/228                 115/40
  **Overweight**      25.0--27.4      **2.47 (1.93, 3.18)**    **5.10 (4.16, 6.25)**   **10.3 (8.00, 13.3)**
                                             765/165                 1,430/497                659/338
                      27.5--29.9      **4.90 (3.12, 7.69)**    **5.82 (4.64, 7.31)**   **13.7 (10.1, 18.6)**
                                             120/41                   867/333                1,375/778
  **Obese**           30.0--34.9                               **6.10 (4.29, 8.66)**   **18.6 (14.6, 23.8)**
                                              22/9                    229/94                2,512/1,646
                         ≥35.0                                                         **31.8 (25.2, 40.2)**
                                               0/0                      9/4                  1,271/980

HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Country-specific estimates are combined using random effects meta-analysis. Sample size and case number stated per cell.

Compared to those with a BMI of 18.5--22.4 kg/m^2^ and normal WC, the HR of diabetes was successively higher at greater levels of BMI and WC, ranging from 1.53 (1.20; 1.95) in men and 1.71 (1.39; 2.09) in women with normal weight at BMI 22.5--24.9 kg/m^2^ and a normal WC, to 22.0 (14.3; 33.8) in men and 31.8 (25.2; 40.2) in women with a BMI greater or equal to 35 kg/m^2^ and a high WC. The HR of diabetes was generally higher (or similar) when comparing people in a lower BMI but higher WC group to those in the BMI group above with a smaller WC, an effect that was particularly pronounced in women. For example, in overweight women, the HR in those with a BMI of 25.0--27.4 kg/m^2^ and a large WC (≥88 cm) was 10.3 (8.00; 13.3), but was 5.82 (4.64; 7.31) in those with a BMI of 27.5--29.9 kg/m^2^ and a moderately increased WC (≥80--87.9 cm).

Cumulative 10-y Incidence of Developing Diabetes {#s3d}
------------------------------------------------

[Figures 5](#pmed-1001230-g005){ref-type="fig"} and [6](#pmed-1001230-g006){ref-type="fig"} show the cumulative incidence of T2D over 10 y of follow-up for different groups of BMI and WC, separately in men and women. [Tables S1](#pmed.1001230.s002){ref-type="supplementary-material"} and [S2](#pmed.1001230.s003){ref-type="supplementary-material"} additionally include cumulative incidences for three different follow-up times (5, 10, 15 y) together with 95% confidence intervals, numbers of events, and person-years of follow-up. The cumulative 10-y incidences estimated in normal weight participants (BMI 18.5--24.9 kg/m^2^) were 1.2%, 2.8%, and 2.2% in men with a normal (\<94 cm), moderately increased (≥94--101.9 cm), and large (≥102 cm) WC; the corresponding figures for women with a normal (\<80 cm), moderately increased (≥80--87.9 cm), and large (≥88 cm) WC were 0.59%, 1.5%, and 2.0%. In overweight individuals, WC distinguished those with incidence rates comparable to normal weight from those with rates equivalent to obese individuals. Cumulative 10--y incidences for men with normal, moderately increased, and large WC were 2.3%, 3.9%, and 7.0% in overweight men and 5.0%, 4.9%, and 10.3% in obese men. Corresponding figures were 1.1%, 2.0%, and 4.4% in overweight women and 2.8%, 2.7%, and 7.4% in obese women, respectively.

![Cumulative incidence of type 2 diabetes over 10 y by BMI and waist circumference groups in men.\
Red line, WC\<94 cm; blue line, WC≥94--101.9 cm; black line, WC≥102 cm.](pmed.1001230.g005){#pmed-1001230-g005}

![Cumulative incidence of type 2 diabetes over 10 y by BMI and waist circumference groups in women.\
Red line, WC\<80 cm; blue line, WC≥80--87.9 cm; black line, WC≥88 cm.](pmed.1001230.g006){#pmed-1001230-g006}

Discussion {#s4}
==========

Results based on 12,403 incident cases of T2D identified in 26 centres in eight European countries as part of the InterAct case-cohort study show independent, significant contributions of both BMI and WC to the risk of T2D. We found greater HRs for WC in women, compared to men, in analyses of standardised, continuous measures as well as using recommended clinical thresholds for abdominal obesity. In terms of absolute risk, 7% of men and 4.4% of women who were overweight and had a large WC at baseline developed diabetes over a 10-y period, placing them at an absolute risk equivalent to or higher than that of obese participants.

Clinical Implications {#s4a}
---------------------

In addition to obese and severely obese individuals at high risk of diabetes, more than a third of the population in the US and UK is overweight [@pmed.1001230-Flegal1],[@pmed.1001230-Zaninotto1]. These individuals\' risk of T2D is much less well defined, despite its potentially greater contribution to the absolute burden of diabetes and related complications. We show that assessment of WC identifies those at high risk of T2D among the large group of individuals who are overweight. Individual lifestyle interventions can reduce diabetes risk [@pmed.1001230-Knowler1], but are not feasible in everyone who is overweight or obese. Current clinical practice relies on BMI to identify overweight and obese individuals at increased risk of diabetes and other adiposity-related morbidity and mortality. Although measurement of WC is often recommended in clinical guidelines, it is rarely actually performed. In a survey of practice nurses in the UK, 96% reported measuring BMI in a typical week, but only 12% measured WC [@pmed.1001230-Brown1]. Recommendations to measure WC on everyone are unlikely to be successful since time pressures are cited as one of the explanations for the implementation gap between recommendations and actual clinical practice. Thus risk prediction models for T2D that assume universal measurement are unlikely to be helpful. As an alternative strategy, practice could focus measurement of WC on subgroups in whom the additional information is likely to make a difference to clinical decision making. Our results suggest that current clinical recommendations should consider the introduction of WC measurement amongst all overweight men and women to identify high-risk individuals for early lifestyle intervention. Normal weight men and women were at sufficiently low absolute risk that measurement of WC would not change their risk categorisation. People in the obese group should already be targeted for individualised lifestyle intervention programmes, and measurement of WC would not alter this recommendation. This observation, of course, does not imply that WC is an unimportant aetiological risk factor in normal weight and obese individuals, but rather that its measurement in these groups does not have an impact on clinical decision making.

Public Health Implications {#s4b}
--------------------------

The frequency of diabetes in combination with its severe long-term complications through organ damage and dysfunction, particularly of the cardiovascular system, create a major public health problem and serious burden on health care systems. Obesity is the strongest risk factor for T2D, and World Health Organization projections estimate that by 2015 approximately 2.3 billion adults will be overweight, more than 700 million will be obese, and diabetes deaths will increase by more than 50% worldwide during this time [@pmed.1001230-World2]. Prevention strategies for T2D require a balance of investment between population-level interventions aimed at shifting the whole distribution of key risk factors and individually focused lifestyle interventions targeted at high-risk individuals. Our results clearly show the value that measurement of WC may have in identifying which people among the large population of overweight individuals are at highest risk of diabetes.

Comparison with Previous Studies {#s4c}
--------------------------------

Previous literature-based reviews have investigated associations between BMI, WC, or other measures of abdominal obesity and incident diabetes [@pmed.1001230-Vazquez1],[@pmed.1001230-Freemantle1],[@pmed.1001230-Abdullah1] and reported similar associations, with risks being approximately twice as large per 1 SD difference in the different obesity measures. Results from the EPIC Potsdam cohort including 1,008 incident T2D cases suggested that the relative risk of T2D associated with WC is smaller in obese than in normal and overweight men and women [@pmed.1001230-Feller1]. We found no evidence for a significant interaction between BMI and WC in men or women in the InterAct study, which includes incident cases from the EPIC Potsdam cohort. Individual studies and meta-analyses investigating the separate and joint contributions of measures of overall and central adiposity have often focused on their respective aetiological relevance [@pmed.1001230-Wang1],[@pmed.1001230-Vazquez1],[@pmed.1001230-Freemantle1],[@pmed.1001230-Feller1]. However, it is difficult to draw inference about the specific role of central and abdominal obesity for diabetes development from epidemiological analyses mutually adjusting for BMI and WC given the strong correlation between these measures and differences in their respective measurement errors [@pmed.1001230-Klein1].

Although associations of BMI and WC with T2D incidence did not differ substantially between countries, and effect estimates of BMI and WC appeared largely consistent, we observed significant heterogeneity in our meta-analyses, with *I* ^2^ values of 48% and 31% for BMI and WC in men and 59% and 69% in women. Meta-regression analyses showed that this heterogeneity was not explained by differences in the average age of participants from the different countries. In contrast, centres with higher average WCs tended to have lower effect estimates of BMI, and inclusion of average WC in meta-regression analyses reduced the *I* ^2^ in men from 48% to 0% and in women from 59% to 52%. Average BMI did not explain heterogeneity in the association between WC and T2D in men and women.

Sex Differences {#s4d}
---------------

We observed a stronger effect estimate for excess abdominal fat in women compared to men using different analytical strategies. This was not due to sex differences in the correlation between WC and BMI, which was similar in both sexes (0.86 in men and 0.87 in women in the subcohort). Also, sex differences in the association between WC and T2D were not explained by height, which was shown to only have a very marginal influence on the association. Previous work has highlighted the value of WC as an index of abdominal fat accumulation when it is interpreted in the context of overall levels of adiposity [@pmed.1001230-Despres1],[@pmed.1001230-Balkau1]. In this study, sex differences in the association between WC and T2D were particularly pronounced after adjusting for BMI. This suggests that WC may be a better measure of abdominal fat and diabetes risk in women once differences in overall body size are accounted for, potentially because of a greater contribution of subcutaneous fat to women\'s WC levels, compared to men.

These results demonstrate that women at greater relative risk of T2D are identified when using recommended, sex-specific WC cut-offs and suggest that cut-offs need to be reviewed if the aim is to target comparable levels of relative risk in men and women. However, if the aim is to target groups based on absolute risk, then the observation that absolute levels of T2D risk are lower in women at any level of WC compared to men is more important.

Strengths and Weaknesses {#s4e}
------------------------

This is the largest study of incident diabetes to date to investigate the separate and joint contributions of BMI and WC. Advantages of our study include its power, prospective design, and international, multicentre population. Inclusion of over 12,000 incident cases allows investigation of T2D risk for different combinations of BMI and WC cut-offs with greater precision. The prospective design of the InterAct case-cohort study minimises systematic error introduced by recall or treatment bias that cross-sectional and case-control studies are subject to. Investigation on a Europe-wide scale increases the generalisability of our findings. However, while the possibility of examining anthropometric effects across the eight European countries can help to understand factors contributing to any potential heterogeneity, results from our European descent InterAct participants do not allow inferences about BMI- and WC-associated relative or absolute risks of T2D in other ethnic groups with potentially different body composition and T2D incidence. Methods for case ascertainment and verification in InterAct are largely based on a clinical diagnosis of T2D. Estimates of the cumulative incidence in InterAct are therefore an underestimation, potentially differential with regard to obesity levels, as rates are expected to be higher if undiagnosed, asymptomatic diabetes cases were also considered. While our large-scale study had standardised measures of anthropometry available for all except 363 Oxford participants, some differences existed between centres in terms of the WC measurement site or the clothes worn during measurement. Assuming that any misclassification was non-differential with regard to case status, this may have led to an attenuation of the observed associations for WC, highlighting the importance of appropriately designed and powered studies with standardised measures of WC to address its relative importance for the risk of diabetes and other outcomes.

Conclusion {#s4f}
----------

WC is independently and strongly associated with T2D, particularly in women, and should be more widely measured. If targeted measurement is necessary for reasons of resource scarcity, measuring WC in overweight individuals may be an effective strategy since it identifies a high-risk subgroup of individuals who could benefit from individualised preventive action.

Supporting Information {#s6}
======================

###### 

**Ratio (women/men) of hazard ratios for the effect of an increased waist circumference (≥102 cm in men and ≥88 cm in women) on incident type 2 diabetes.**

(TIF)

###### 

Click here for additional data file.

###### 

**Cumulative incidence of type 2 diabetes by BMI and waist circumference in men.**

(DOC)

###### 

Click here for additional data file.

###### 

**Cumulative incidence of type 2 diabetes by BMI and waist circumference in women.**

(DOC)

###### 

Click here for additional data file.
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